| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) |
|
11814.35 | -266.50 | -2.21% |
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Vimta Labs Limited (NSE: VIMTALABS)
VIMTALABS Technical Analysis
4
| As on 25th Feb 2020 VIMTALABS Share Price closed @ 97.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 133.31 & Sell for SHORT-TERM with Stoploss of 98.70 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VIMTALABS Share Price
| Open | 101.40 | Change | Price | % |
| High | 101.50 | 1 Day | -2.20 | -2.21 |
| Low | 96.00 | 1 Week | -2.80 | -2.80 |
| Close | 97.25 | 1 Month | -3.50 | -3.47 |
| Volume | 7842 | 1 Year | -100.20 | -50.75 |
| 52 Week High 221.00 | 52 Week Low 87.50 | ||||
NSE INDIA Most Active Stocks
| IDEA | 3.95 | 2.60% |
| YESBANK | 35.15 | 0.57% |
| SUZLON | 2.85 | 7.55% |
| GMRINFRA | 25.55 | 0.39% |
| TATAMOTORS | 149.90 | -0.50% |
| ASHOKLEY | 80.65 | -5.06% |
| SBIN | 326.80 | 1.19% |
| IBULHSGFIN | 324.70 | -1.86% |
| INDIACEM | 87.05 | 17.24% |
| SAIL | 39.25 | 0.00% |
NSE INDIA Top Gainers Stocks
| VIVIDHA | 0.30 | 20.00% |
| SPYL | 0.30 | 20.00% |
| NAVINFLUOR | 1454.30 | 20.00% |
| DPSCLTD | 7.60 | 19.69% |
| INDIACEM | 87.05 | 17.24% |
| DNAMEDIA | 0.35 | 16.67% |
| GTLINFRA | 0.40 | 14.29% |
| IMPEXFERRO | 0.40 | 14.29% |
| SURANAT&P | 4.00 | 14.29% |
| PSL | 0.50 | 11.11% |
NSE INDIA Top Losers Stocks
| VIMTALABS Daily Charts |
VIMTALABS Intraday Charts |
Whats New @ Bazaartrend |
VIMTALABS Free Analysis |
|
|
VIMTALABS Important Levels Intraday
| RESISTANCE | 107.85 |
| RESISTANCE | 104.45 |
| RESISTANCE | 102.35 |
| RESISTANCE | 100.25 |
| SUPPORT | 94.25 |
| SUPPORT | 92.15 |
| SUPPORT | 90.05 |
| SUPPORT | 86.65 |
VIMTALABS Target for Month February
| 4th UP TARGET | 164.53 |
| 3rd UP TARGET | 147.01 |
| 2nd UP TARGET | 136.18 |
| 1st UP TARGET | 125.35 |
| 1st DOWN TARGET | 94.45 |
| 2nd DOWN TARGET | 83.62 |
| 3rd DOWN TARGET | 72.79 |
| 4th DOWN TARGET | 55.27 |
VIMTALABS Weekly Target
| 4th UP TARGET | 125.21 |
| 3rd UP TARGET | 117.70 |
| 2nd UP TARGET | 113.06 |
| 1st UP TARGET | 108.42 |
| 1st DOWN TARGET | 95.18 |
| 2nd DOWN TARGET | 90.54 |
| 3rd DOWN TARGET | 85.90 |
| 4th DOWN TARGET | 78.39 |
VIMTALABS Target for Year 2020
| 4th UP TARGET | 548.49 |
| 3rd UP TARGET | 402.33 |
| 2nd UP TARGET | 311.99 |
| 1st UP TARGET | 221.64 |
| 1st DOWN TARGET | -36.14 |
| 2nd DOWN TARGET | -126.49 |
| 3rd DOWN TARGET | -216.83 |
| 4th DOWN TARGET | -362.99 |
Vimta Labs Limited ( NSE INDIA Symbol : VIMTALABS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VIMTALABS Synopsis Technicals View
| 50 Day EMA |
Close is Below EMA 50 (Short Term) |
Bearish | |
| 100 Day EMA | Close is Below EMA 100 (Mid Term) | Bearish | |
| 200 Day EMA | Close is Below EMA 200 (Long Term) | Bearish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is 47.08 | Sideways | |
| MFI (14) | MFI is 53.69 | Sideways | |
| CCI (20) | CCI is -72.60 | Sideways | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Above -DI | Up Trend | |
| PSAR | Stoploss For Short Sell | 117.39 | |
| 10 Day Avg Volume | Traded -7.54 % Less then 10 Day Average Volume | ||
VIMTALABS Other Details
| Segment | EQ | |
| Market Capital | 0.00 | |
| Sector | Healthcare | |
| Industry | Medical Laboratories & Research | |
| Offical website | http://www.vimta.com | |
VIMTALABS Address
 |
Plot Nos.: 142/2 and 142 IDA Phase II Hyderabad, 500051 India Phone: 91 40 2726 4141 Fax: 91 40 2726 3657 |
|
VIMTALABS Latest News
| Should You Be Concerned About Mitula Group Limited's (ASX:MUA) Earnings Growth? - Simply Wall St - 16th Jul 18 |
| Why Servcorp Limited (ASX:SRV) Is An Attractive Stock On Right Now - Simply Wall St - 19th Jun 18 |
| Spotlight On Vimta Labs Limited's (NSE:VIMTALABS) Fundamentals - Simply Wall St - 14th Jun 18 |
| Mesa Adaptive Average of Vimta Labs Limited (VIMTALABS.NS) Holding Above ... Kaplan Herald - 18th May 18 |
| VIMTA Labs donates vehicle to Akshaya Patra Foundation The Hans India - 18th May 18 |
| Vimta Labs Ltd Board recommends Dividend of Rs. 2 for 2017-18 Equity Bulls - 12th May 18 |
| BRIEF-India's Vimta Labs March-Qtr Profit Almost Doubles Reuters - 11th May 18 |
| Vimta Labs Ltd calls for board meeting on May 10, 2018 Equity Bulls - 02nd May 18 |
| Share Activity Lifted for Vimta Labs Limited (VIMTALABS.NS) in Session Newberry Journal - 22nd Mar 18 |
| Vimta Labs Limited (VIMTALABS.NS) TMF Reaching A Key Level Wall Street Herald - 21st Feb 18 |
VIMTALABS Business Profile
Vimta Labs Limited provides contract research and testing services primarily in India. It offers analytical testing services for food and agriculture products, and drugs and pharmaceuticals, as well as tests water samples for various purposes and specifications. The company also provides environmental assessment services, including site selection and liability studies; environmental impact assessments; environment management plans; carrying capacity based regional studies; environmental audits; solid and hazardous waste management; risk assessments and disaster management plans; occupational health and safety, industrial hygiene; environmental baseline monitoring for air, meteorology, water, soil, noise, ecology, socio-economic, demography, etc.; industrial emission source monitoring; offshore sampling and analysis of marine water and sediments; marine ecological studies; marine impact assessment; rehabilitation and resettlement studies; forestry and ecological studies; geo-technical studies; geological and hydro-geological studies; land use/ land cover studies based on remote sensing; socio-economic studies; due diligence studies; epidemiological studies; wasteland management studies; and study on bio-indicators, as well as offers various other services under environment chemistry. In addition, it provides clinical research services, including Phase-I/ bioequivalence studies, as well as screening and recruitment services; and conducts studies on arious dosage forms, such as tablets, capsules, extended release preparations, gels, jellies, transdermal patches, injectibles, etc. Further, the company offers clinical reference lab services; pre-clinical services, including drug discovery services to pharmaceutical and biotech companies in the areas of pharmacology, DMPK/ADME, toxicology, and bioanalytical; and services in the area of cell and molecular biology. Vimta Labs Limited was founded in 1984 and is based in Hyderabad, India.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
